

# **L** Core Project R030D030604

#### O Details

| Projects        | Name   | Award        | Publications   | Repositories   | Analytics    |
|-----------------|--|--------------|----------------|----------------|--------------|
| 1R03OD030604-01 | Using Common Fund data to inform rare disease preclinical models and prioritize drug repurposing | \$297,000.00 | 9 publications | 0 repositories | 0 properties |

### Publications

Published works associated with this project.

| ID         | Title  | Authors              | R<br>C<br>R | SJ<br>R  | Cita<br>tion<br>s | Cit./<br>yea<br>r | Journal                       | Publ<br>ishe<br>d | Updat<br>ed |
|------------|--|----------------------|-------------|----------|-------------------|-------------------|-------------------------------|-------------------|-------------|
| 35337371 🗹 | Considerations and challenges for sexaware drug repurposing. | Jennifer<br>L Fisher | 1.<br>46    | 2.<br>03 | 9                 | 4.5               | Biology of Sex<br>Differences | 2,02<br>2         | Oct<br>26,  |

|  |  | 4<br>more<br>Brittany<br>N<br>Lasseign<br>e                    |          |               |   |   |                                  |           | 2024<br>(1<br>mont<br>h ago)               |
|--|--|--|----------|---------------|---|---|----------------------------------|-----------|--|
| 37533331 🗹<br>DOI 🗗                      | Evaluating cancer cell line and patient-<br>derived xenograft recapitulation of<br>tumor and non-disease | Avery S Williams2 more Brittany N Lasseign e                   | 1.<br>05 | 0             | 3 | 3 | Cancer Rep<br>(Hoboken)          | 2,02<br>3 | Oct<br>26,<br>2024<br>(1<br>mont<br>h ago) |
| <u>36602970</u> <b>♂</b><br>DOI <b>♂</b> | Ten simple rules for using public biological data for your research.                                     | Vishal H<br>Oza<br>9<br>more<br>Brittany<br>N<br>Lasseign<br>e | 0.<br>61 | 1.<br>65<br>2 | 2 | 2 | PLoS<br>Computational<br>Biology | 2,02<br>3 | Oct<br>26,<br>2024<br>(1<br>mont<br>h ago) |
| 37824797 🗗                               | Computational Advancements in Cancer Combination Therapy Prediction.                                     | Victoria<br>L Flanary<br>3<br>more<br>Brittany                 | 0.<br>46 | 2.<br>24<br>9 | 2 | 2 | JCO Precision<br>Oncology        | 2,02      | Oct<br>26,<br>2024<br>(1                   |

|                     |  | N<br>Lasseign<br>e  |          |               |   |   |                       |           | mont<br>h ago)                             |
|---------------------|--|---|----------|---------------|---|---|-----------------------|-----------|--|
| 37217845 🗹<br>DOI 🗹 | Prioritized polycystic kidney disease<br>drug targets and repurposing<br>candidates from pre-cystic and  | Elizabet<br>h J Wilk<br>9<br>more<br>Brittany<br>N<br>Lasseign<br>e | 0.<br>39 | 1.<br>44<br>6 | 1 | 1 | Molecular<br>Medicine | 2,02<br>3 | Nov 8,<br>2024<br>(4<br>weeks<br>ago)      |
| 37090499 ☑<br>DOI ☑ | Evaluating cancer cell line and patient-<br>derived xenograft recapitulation of<br>tumor and non-disease | Avery S Williams2 more Brittany N Lasseign e                        | 0        | 0             | 0 | 0 | bioRxiv               | 2,02<br>3 | Oct<br>26,<br>2024<br>(1<br>mont<br>h ago) |
| 37362157 🗗<br>DOI 🗗 | Sex-biased gene expression and gene-<br>regulatory networks of sex-biased<br>adverse event drug targets  | Jennifer<br>L Fisher<br>2<br>more<br>Brittany<br>N<br>Lasseign<br>e | 0        | 0             | 0 | 0 | bioRxiv               | 2,02<br>3 | Oct<br>26,<br>2024<br>(1<br>mont<br>h ago) |

| 38167211 🗗          | Sex-biased gene expression and gene-<br>regulatory networks of sex-biased<br>adverse event drug targets  | Jennifer L Fisher2 more Brittany N Lasseign e                       | 0 | 0.<br>71      | 0 | 0 | BMC<br>pharmacology<br>&<br>toxicology | 2,02<br>4 | Oct<br>26,<br>2024<br>(1<br>mont<br>h ago) |
|---------------------|--|---|---|---------------|---|---|--|-----------|--|
| 38531616 🗹<br>DOI 🗗 | Signature reversion of three disease-<br>associated gene signatures prioritizes<br>cancer drug repurposi | Jennifer<br>L Fisher<br>7<br>more<br>Brittany<br>N<br>Lasseign<br>e | 0 | 0.<br>78<br>9 | 0 | 0 | FEBS Open Bio                          | 2,02<br>4 | Oct<br>26,<br>2024<br>(1<br>mont<br>h ago) |

## Notes

RCR Relative Citation Ratio

SJR Scimago Journal Rank



#### Notes

Repository For storing, tracking changes to, and collaborating on a piece of software.

PR "Pull request", a draft change (new feature, bug fix, etc.) to a repo.

Closed/Open Resolved/unresolved.

Avg Issue/PR Average time issues/pull requests stay open for before being closed.

Only the main /default branch is considered for metrics like # of commits.

# of dependencies is totaled from all manifests in repo, direct and transitive, e.g. package.json + package-lock.json.

### Analytics

Traffic metrics of websites associated with this project.

#### Notes

Active Users <u>Distinct users who visited the website</u> **?**.

New Users <u>Users who visited the website for the first time</u> **.** 

Engaged Sessions <u>Visits that had significant interaction</u> **?**.

Generated on Dec 4, 2024

Developed with support from NIH Award U54 OD036472

<sup>&</sup>quot;Top" metrics are measured by number of engaged sessions.